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Abstract
In this study, we established new systematic protocols for the preparation of cDNA clones, convention-
ally termed open reading frame (ORF) clones, suitable for characterization of their gene products by
adopting a restriction-enzyme-assisted cloning method using the Flexi
w cloning system. The system has fol-
lowing advantages: (1) preparation of ORF clones and their transfer into other vectors can be achieved
efﬁciently and at lower cost; (2) the system provides a seamless connection to the versatile HaloTag
w
labeling system, in which a single fusion tag can be used for various proteomic analyses; and (3) the resul-
tant ORF clones show higher expression levels both in vitro and in vivo. With this system, we prepared ORF
clones encoding 1929 human genes and characterized the HaloTag-fusion proteins of its subset that are
expressed in vitro or in mammalian cells. Results thus obtained have demonstrated that our Flexi
w ORF
clones are efﬁcient for the production of HaloTag-fusion proteins that can provide a new versatile set
for a variety of functional analyses of human genes.
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1. Introduction
The entire human genome sequence has allowed us
to create a provisional catalog of human transcripts
and proteins by a combination of computational
predictions and information from experimentally
collected cDNA sequences.
1 Although approximately
23 000 protein-coding genes have been assigned to
the human genome by the Ensembl database (NCBI
built 36, Ensembl 48; http://www.ensembl.org/
Homo_sapiens/index.html),
2 the functional roles of
the respective gene products remains to be exper-
imentally explored. Because of the importance of
these studies, many groups have started to collect a
set of protein-coding sequences, conventionally
termed open reading frames (ORFs), in a genome-
wide manner, so-called ‘ORFeome cloning’. ORF
clones serve as versatile reagents for the functional
and structural studies of proteins.
3–5 Therefore,
various systems have been developed to enable efﬁ-
cient large-scale cloning and expression of ORF
clones. Currently available systems rely on either
site-speciﬁc recombinases or rare-cutting restriction
enzymes for the transfer of ORFs between expression
vectors. These systems allow the correct
orientation and reading frame to be maintained
after transfer.
6–8 The Gateway and Creator cloning
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based systems, transfer ORFs by l-att recombination
using the 25-bp attB site, and Cre-loxP recombination
using the 34-bp lox-P site upstream of the ORF,
respectively.
7 On the other hand, restriction-
enzyme-based systems are less frequently used at
present, although a commercial system has recently
emerged that is as efﬁcient as those based on recom-
binases. The Flexi
w cloning system can manipulate
ORFs using rare-cutting restriction enzymes, SgfI and
PmeI, after the addition of these 8-bp restriction
sites to the ﬂanking 50 and 30 ends of the ORFs,
respectively.
8 We previously prepared a set of ORF
clones for human KIAA genes using a Gateway-type
vector.
9 Furthermore, we created the ORF clones as
fusion proteins with green-ﬂuorescent protein to
analyze the subcellular localization of the proteins in
cultured cells and to evaluate the in vitro expression
of ORF clones.
9 However, when we wish to carry out
alternative functional studies beyond bioimaging,
the Gateway system requires re-construction of
appropriate expression plasmids for the creation of
differently tagged proteins. This creates a serious
bottleneck in the use of our large ORF clone set for
functional genomics analysis. Thus, we started to
look for a more versatile tag system that would
allow us to carry out both bioimaging and biochemi-
cal experiments using a single tag. Within this context,
we considered a recently emerging technology, com-
mercially designated as HaloTag
w technology.
10 This
technology is quite attractive since HaloTag can be
used not only for bioimaging, but also for various pro-
teomic applications involving fusion protein immobil-
ization. Although similar technologies have been
developed, such as SNAP-tag which uses a modiﬁed
human O
6-alkylguanine DNA alkyl transferase as the
tag,
11,12 we preferred HaloTag
w technology because
we felt it may be more suitable for studies in
mammals. Haloalkane dehalogenase, the enzyme
from which HaloTag is derived, does not exist in mam-
malian cells, unlike O
6-alkylguanine DNA alkyl trans-
ferase. Since HaloTag
w technology was available in
the Flexi
w cloning system, we were strongly motivated
to examine whether the Flexi
w cloning method was
suitable for preparation of a large number of ORF
clones, and whether it would be useful for down-
stream functional characterization.
In this study, we prepared nearly 2000 ORF clones
using the Flexi
w cloning method, and the resultant
ORF clones were examined with respect to production
in cell-free protein synthesis systems as HaloTag-
fusion proteins. The results indicated that the Flexi
w
cloning method was as efﬁcient as the Gateway
cloning method and that the Flexi ORF clones
consistently produced equal or larger amounts of
HaloTag-fusion proteins than Gateway clones in in
vitro protein production systems. We also examined
the subcellular localizations of 40 HaloTag-fusion pro-
teins in HEK293 cells and conﬁrmed that the results
were equivalent to those of the corresponding
Monster Green
w Fluorescent Protein (MGFP)-fusion
proteins. Taken together, these results indicate that
the Flexi ORF clone set can perform efﬁcient func-
tional analyses of human genes and provide an
alternative resource for the human ORFeome project.
2. Materials and methods
2.1. Materials
pTD1 plasmid was obtained from Shimadzu (Kyoto,
Japan). pF1Kof vector, which was constructed by ﬂip-
ping the AccIII–AgeI 832-bp DNA fragment including
the origin of replication in the pF1KT7 (Promega,
Madison, USA) vector, was kindly provided by
Promega Corporation. pF3AHT vector was constructed
by inserting the blunt-ended EcoICRI–SalI 946-bp
DNA fragment from the pFC8A (HT) vector
(Promega) into the EcoICRI site of the pF3A WG
(BYDV) (Promega) vector backbone in the appropriate
order for production of a C-terminal HaloTag-fusion
protein. pFC8A (MGFP) was constructed by replacing
the HaloTag gene with the MGFP gene from the
phMGFP vector (Promega). For construction of
HaloTag-fusion KIAA protein expression clones in the
pTD2-Gateway and pTD2-Flexi vectors, KIAA ORFs
with the HaloTag sequence were extracted from
pF3AHT ORF clones. The ORFs for the synthetic
ﬁreﬂy luciferase gene (luc2), HaloTag, and Venus
were obtained from pGL4.10[luc2], pFC8A vector
(Promega), and (EYFP-F46L/V68L/M153T/V163A/
S175G)/pCS2 kindly provided by Dr. Atsushi
Miyawaki (Brain Science Institute, RIKEN),
13 respect-
ively, by PCR and were subcloned into the pF1KT7
Flexi vector. Each ORF was transferred to seven differ-
ent kinds of modiﬁed pTD2 expression vectors whose
cloning sites were ﬂanked at both sides with speciﬁed
sequences. The D5 vector, which carried a 10-bp
sequence (AATCGAATTC) in place of the 50-polyhedrin
enhancer sequence, was also used in the preparation
of the luc2 expression plasmid. pFC8KHT-Memb,
pFC8KHT-NLS, pFC8KHT-ER, pFC8KHT-Golgi, and
pFC8KHT-Mito were constructed by ligation of DNA
fragments containing localization signal sequences,
with the pFC8K (HaloTag) vector digested by SgfI
and EcoICRI (Carboxy Flexi
w System, Promega). The
localization signal fragments (abbreviated as Memb,
NLS, ER, Golgi, and Mito) were ampliﬁed by PCR
from the following expression clones (BD, Franklin
Lakes, USA) with each primer appended by SgfIo r
PmeI sites at the 50 end: Memb, a membrane-localized
signal from N-terminal sequence of neuromodulin
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a triple repeat of NLS from SV40 large T-antigen
(pDsRed2-Nuc); ER, an endoplasmic reticulum (ER)
targeting sequence from calreticulin (pDsRed2-ER);
Golgi, a Golgi-localized signal from beta 1,4-galacto-
syltransferase (pEYFP-Golgi); and Mito, a mitochon-
drial targeting sequence from subunit VIII of
cytochrome c oxidase (pDsRed2-Mito). HaloTag Cy5
ligand was prepared by the coupling of HaloTag
Amine (O4) ligand (Promega) and Cy5 Mono-
Reactive Dye Protein Array Grade (Amersham
Biosciences, Piscataway, USA) according to the manu-
facturer’s instructions. Anti-HaloTag IgG was gener-
ously provided by Promega Corporation. Escherichia
coli strain JC8679 (recB21, recC22, sbcA23, thr-1,
leuB6, phi-1, lacY1, galK2, ara-14, xyl-5, mtl-1,
proA2, his-4, argE3, rpsL31, tsx-33, supE44, his-328)
was obtained from the Health Science Research
Resources Bank (HSRRB) of the Japan Health
Sciences Foundation.
2.2. Preparation of Flexi ORF clones
The ORF of interest was ampliﬁed from 1 to 4 ng of
a plasmid DNA using 0.5 units of PrimeSTARTM
HS DNA polymerase (Takara Bio, Shiga, Japan) in a
20-mL PCR reaction mixture that included 0.2 mM
each of four dNTPs and 0.5 mM each of the gene-
speciﬁc primers (50-CCCCGCGATCGCCATG N17-30
and 50-CCCCGTTTAAAC N20-30, where N17 indicates
a 17 nt-sense sequence downstream from the start
methionine codon of ORF and N20 indicates a 20
nt-anti-sense sequence upstream from the stop
codon), under the following PCR conditions: 958C
for 2 min/30 cycles of 988C for 10 s and 688C for
3m i n /688C for 5 min. In some cases, 0.5 units of
KOD-Plus-DNA Polymerase (Toyobo, Osaka, Japan)
was used in a 25-mL PCR reaction mixture that
included 0.2 mM each of four dNTPs, 1 mM MgCl2
and 0.3 mM each of the gene-speciﬁc primers under
the following PCR conditions: 948C for 2 min/30
cycles of 988C for 10 s, 558C for 30 s/688C for
3 min. One-third of the resultant ampliﬁed PCR pro-
ducts was digested by SgfI and PmeI in a 10-mL reac-
tion mixture of Flexi
w buffer with 1  Flexi
w Enzyme
Blend (SgfI and PmeI) (Promega) for 30 min at 378C
after puriﬁcation of the PCR products using Wizard
SV 96 PCR Clean-Up System (Promega). After inacti-
vation of the restriction enzymes by incubation for
20 min at 658C, one-sixth of the digested PCR
product was ligated with 25 ng of the SgfI- and
PmeI-digested pF1K T7 vector in a 10-mL reaction of
Flexi
w Ligase buffer with 10 units of T4 DNA Ligase
(Promega) for 60 min at 258C. One microliter of the
ligation reaction was used to transform 10 mLo f
JM109 Competent Cells (.10
8 cfu/mg, Promega),
and the transformants were selected on LB agar
plates containing 50 mg/mL of kanamycin. A ran-
domly chosen clone was ﬁrst examined using the
CloneCheckerTM System (Invitrogen, Carlsbad, USA)
by estimating the size of the supercoiled plasmid
DNA. For ORFs cloned by the PCR cloning method,
entire sequences were determined with the BigDye
Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems, Foster City, USA), with sequencing
primers designed every approximate 400 bp in a
single strand of ORF. The sequence data were obtained
with ABI PRISM 3700 or 3130, and analyzed with
SEQUENCHERTM sequence assembly software (Gene
Codes Co., Ann Arbor, USA). For ORF Trap cloning,
the ORF of interest was transferred to pF1Kof vector
using a homologous recombination system in E. coli
(JC8679), according to the method previously
described.
9 For Flexi
w Vector cloning using the pENT
entry clones we had previously constructed,
9 the
ORF of interest was recovered by digestion with BstBI
and SnaBI restriction endonucleases whose recog-
nition sites were located upstream and downstream
of the ORF, respectively, in the vector portion. It was
then inserted between the BstBI and SnaBI sites of
the pSP73Flexi-1 vector, which contains SgfI and
PmeI sites upstream and downstream of the BstBI
and SnaBI sites, respectively. After cloning the ORFs
into the pSP73Flexi-1 vector, they were cut with SgfI
and PmeI restriction endonucleases and then re-
cloned between the SgfI and PmeI sites of the pF1K
vector.
2.3. In vitro protein production
For in vitro translation systems using Wheat Germ
Extract Plus (WGEP) (Promega) and a TransDirect
insect cell lysate (TD) (Shimadzu, Japan), RNA syn-
thesis was performed using the T7 RiboMAX Express
Large Scale RNA Production System (Promega) with
linearized template DNAs, according to the supplier’s
instructions. After puriﬁcation with the RNeasy Mini
Kit (QIAGEN, Hilden, Germany), RNAs were concen-
trated by ethanol precipitation and dissolved in
15 mL of DEPC-treated water. In vitro translation reac-
tions were performed in a reaction volume of 10 mL
using 2.4 and 3.2 mg of the RNA for the WGEP and
the TD systems, respectively, following the supplier’s
recommendation unless otherwise stated. For the
TNT SP6 High-Yield Protein Expression (HYPE) System
(Promega), approximately 400 ng of TempliPhi-
ampliﬁed pF3AHT HaloTag-fusion protein expression
clones were used as a template in a 10-mL reaction,
according to the manufacturer’s instructions. For
production of radiolabeled proteins, 2.86 mCi of
35S-labeled Redivue Promix (a mixture of L-
[
35S]methionine and L-[
35S] cysteine) (GE Healthcare,
No. 3] T. Nagase et al. 139USA) was added in the reaction. The TempliPhi (GE
Healthcare) reaction was conducted by denaturation
of 10–30 ng of DNAs with 5 mL of Denature buffer
for 3 min at 95ºC followed by polymerization for
16 h at 30ºC. For the HaloTag tetramethylrhodamine
(TMR) ligand labeling of the in vitro produced
HaloTag-harboring proteins, 2.3 mLo f1mM
HaloTag-TMR ligand (Promega) was added after the
in vitro reaction (10 mL) and the mixture was incu-
bated for 5–10 min at room temperature. After the
addition of 4.2 mLo f4   Laemmli’s SDS sample
buffer, the products were resolved on a MDG-267
Real Gel Plate (concentration gradient: 5–10%;
Biocraft, Japan) by polyacrylamide gel electrophoresis
in the presence of SDS (SDS–PAGE).
2.4. Examination of the effects of the ﬂanking
sequences of ORF on in vitro production of
luciferase, Venus, and HaloTag
For in vitro luc2 production, 1.4 mg of RNAs were
used for WGEP and 3.8 mg for TD in a reaction
volume of 12 mL. The activities of luc2 in an aliquot
of the reaction mixture (10 mL) were assayed
using the Dual-Glo Luciferase Assay System
(Promega) according to the supplier’s instructions.
Luminescence was detected in a GloMAX 96
Microplate Luminometer (Promega). In vitro synth-
eses of Venus proteins were performed in 20 mL
using 4.8 and 6.4 mg of the template RNA in the
WGEP and the TD systems, respectively, after removing
turbidity by centrifugation at 15 000 rpm for 2 min.
Fluorescent signals were detected in the Applied
Biosystems 7500 Fast Real-Time PCR System after 2
and 5 h reactions in the WGEP and TD systems,
respectively. HaloTag-TMR ligand binding was moni-
tored for quantiﬁcation of the active HaloTag
protein. Two microliters of 5 mM HaloTag-TMR
ligand was added to an 8-mL reaction mixture, and
the mixture was incubated at 258C for 5 min. The
binding reaction was stopped by adding 2 mLo f6  
Laemmli’s SDS sample buffer and then boiling at
1008C for 5 min. The solution (7.5 mL) was analyzed
on 12.5% SDS–PAGE. Fluorescent signals from TMR
were detected and quantiﬁed with FLA-3000
(Fujiﬁlm, Tokyo, Japan) and MultiGauge image analyz-
ing software (Fujiﬁlm).
2.5. Western blotting
For Western blot analysis of HaloTag-fusion
proteins, the proteins separated by SDS–PAGE were
electrophoretically transferred onto a PVDF mem-
brane (FluoroTrans W; PALL, Portsmouth, UK) using
the transfer buffer [25 mM Tris–Cl (pH 8.3),
192 mM glycine, 20% (V/V) methanol] with the
BIOCRAFT BE-300 semidry transfer device (Biocraft,
Tokyo, Japan). HaloTag-fusion proteins were detected
as follows. The resultant PVDF membrane was washed
with TBS [20 mM Tris–Cl (pH 7.5) and 150 mM
NaCl] including 0.05% Tween-20 (TBST) for 10 min
with gentle agitation. After pre-incubation of the
membrane with TBST containing 5% skim milk for
60 min, the membrane was incubated with 1:30
000 rabbit anti-HaloTag IgG antibody (Promega) in
TBST containing 1% skim milk for 60 min. After
washing with TBST for 5 min four times, the
membrane was further incubated with 1:30 000
horseradish-peroxidase-conjugated anti-rabbit IgG
antibody (Promega) in TBST containing 1% skim
milk for 60 min. After washing the membrane with
TBST, HaloTag-fusion proteins were ﬁnally detected
using ECL plus (GE Healthcare) according to the
manufacturer’s instructions. The luminescent images
were recorded by a Luminescent Image Analyzer
LAS3000 (Fujiﬁlm). MagicMark XP Western Protein
Standard (Invitrogen) was used for estimation of the
apparent molecular masses of the HaloTag-fusion
proteins.
2.6. Examination of the subcellular localization of
HaloTag-fusion proteins
The human embryonic kidney (HEK) 293 cell line
was obtained from HSRRB of the Japan Health
Sciences Foundation. HEK293 and COS-7 cell lines
were grown in DMEM supplemented with 10% of
Tet System Approved Fetal Bovine Serum (BD) and
1  Antibiotic–Antimycotic reagent (100 U/mL
penicillin þ 100 mg/mL streptomycin þ 0.25 mg/mL
amphotericin B; Invitrogen). HEK293 and COS-7
were transfected with expression clones using
FuGENE6 Transfection Reagent (Roche Diagnostics,
Basel, Switzerland) in an 8-well chambered coverglass
(Thermo Fisher Scientiﬁc, Rochester, USA) according
to the supplier’s instructions. Cells (200 mL, 4  
10
4) were plated 24 h before transfection. After
16–24 h of transfection, HaloTag-fusion proteins
and DNA were labeled with medium with 1 mMo f
HaloTag-TMR ligand and Hoechst (33342, 3.3 mg/
mL, ﬁnal concentration; Sigma-Aldrich, St. Louis,
USA) for 15 min in a CO2 (5%) incubator at 37ºC.
After washing four times with 300 mL of medium,
the cells were incubated for 0.5–24 h in a CO2 incu-
bator and the subcellular localization of HaloTag- or
MGFP-fusion proteins were observed with a Biozero
ﬂuorescence microscopy system (Keyence, Osaka,
Japan) with 605/55 and 535/50 nm ﬁlters. Photos
labeled with Hoechst33342 were merged with
those of MGFP- or HaloTag-fusion proteins and the
subcellular localizations of MGFP- and HaloTag-
fusion proteins were compared.
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3.1. Construction of Flexi ORF clones
Led by the motivation described in Section 1, we
have initiated preparation of Flexi
w Vector ORF
clones using human cDNA clones accumulated by
the Kazusa cDNA project.
14,15 So far, 1929 Flexi
ORF clones have been constructed in a pF1K
vector format. The list of the Flexi ORF clones
is accessible at www.dnaresearch.oxfordjournals.org
(Supplementary Table S1). These Flexi ORF clones
contained relatively large ORFs derived from 1163
KIAA and 766 known genes, the average sizes of
which are 2.8 and 2.4 kb, respectively. ORFs of 341
pF1K clones were PCR-cloned using PrimeStar HS or
KOD plus high-ﬁdelity DNA polymerases, as described
in Section 2. All ORF clones obtained by PCR cloning
were sequence-veriﬁed and we found that the PCR
mutation occurrence rate was less than 5   10
25
mutations per residue under the conditions employed
in this study. ORF clones with large ORFs are inevitably
at higher risk of having artiﬁcial missense mutation(s)
introduced by PCR, thus we previously developed and
applied the ORF Tap cloning method for the construc-
tion of Flexi ORF clones for some relatively long ORFs
(mainly those .2 kb).
9 The method is based on a
homologous recombination in E. coli JC8679 and
thus is very unlikely to introduce mutation(s) into
ORFs during cloning. We therefore considered that
this method was also highly suited to the preparation
of Flexi ORF clones because reconﬁrmation of the ORF
sequence could be avoided.
16–18 Within this context,
842 pF1K clones were constructed by the ORF Trap
cloning method. The remaining 749 pF1K clones,
termed Flexi_RBS type, were constructed by transfer-
ring ORF sequences from the Gateway entry clones
we had previously prepared to the pF1K vector,
because the 50- and 30-untranslated sequences
(UTRs) have been already trimmed out in the
Gateway entry clones. These clones contained a 19-
bp fragment, including a ribosome-binding site
(RBS), between the SgfI site and a translational
initiation codon. These Flexi clones were distinguished
from others by adding ‘SD’, representing a Shine-
Dalgarno sequence as an indication of the presence
of an RBS, to their clone IDs, whereas the other
pF1K clones were simply termed Flexi type. The ORF
ﬂanking sequences in these Flexi clones are shown
in Fig. 1A. The SgfI site was placed one base upstream
of the initiation codon, which allowed the production
of recombinant proteins with the native translational
initiation site or with N-terminal tags using appropri-
ate Flexi
w vectors. On the other hand, the PmeI site
was placed just downstream from the original stop
codon of the ORF, which resulted in an attachment
of the Val in Flexi type or the Tyr–Val–Val in
Flexi_RBS type to the carboxy end of the native ORF.
When an ORF sequence ﬂanked by SgfI and PmeI
was cloned between the SgfI and EcoICRI sites of a
Flexi
w vector, the translational stop codon was
destroyed and thus the protein was expressed as a
carboxy-terminal fusion. ORFs in pF1K clones thus
prepared can be easily transferred to other types of
Flexi
w vectors following digestion with SgfI and PmeI
(Fig. 1B).
Information about the Flexi ORF clones (i.e. ORF
nucleotide sequences, the predicted primary
sequences of the gene products, corresponding
Ensembl gene ID, and gene description
2 in addition
to results of computer-assisted analyses of the pre-
dicted primary amino acid sequences) is available
through our KOP database (http://www.kazusa.or.jp/
kop/).
3.2. Comparison of the productivities of HaloTag-
fusion proteins from Flexi ORF clones and Gateway
ORF clones in two in vitro protein production
systems
Since our focus is on the use of HaloTag
w technol-
ogy, we initially prepared a set of Flexi ORF clones as
HaloTag-fusions using the Flexi
w cloning method. To
examine the utility of HaloTag
w technology,
HaloTag-fusion products were produced in in vitro
translation systems. The expressed proteins were ana-
lyzed on SDS–PAGE after labeling with a HaloTag-TMR
ligand. This simple labeling procedure enabled us to
ﬂuorometrically detect only proteins carrying a
HaloTag portion on SDS–PAGE, and thereby made it
easy to check whether the ORF encoded an appropri-
ately sized protein. Using this analysis, quantities of
HaloTag-fusion proteins with ligand-binding activity
could be directly estimated from the ﬂuorescence
intensities of protein bands on SDS–PAGE. In these
experiments, we also compared the performance of
two in vitro translation systems: one derived from a
wheat germ extract and the second from an insect
cell extract [commercially named WGEP and
TransDirect (TD), respectively]. We used these
systems because these eukaryotic cell extracts are
known to produce larger amounts of proteins than
conventional rabbit reticulocyte lysates. In parallel,
we also compared the efﬁciency of protein synthesis
by Gateway-type (pTD2-Gw) and Flexi-type (pTD2-
Flx) expression constructs, where ORFs were ﬂanked
with different appended sequences that are associ-
ated with the respective cloning methods. These
appended sequences may affect the translational
activity of the HaloTag-fusion constructs in vitro.F o r
this purpose, we constructed 13 sets of HaloTag-
fusion protein expression plasmids using pTD2-Gw
No. 3] T. Nagase et al. 141Figure 1. ORF transfer in the Flexi
w Vector cloning system. (A) Flanking sequences of ORF in Flexi clones. Recognition sequences of SgfI and
PmeI are indicated as green and red characters, respectively. The nucleotide sequence corresponding to the ribosomal binding site is
underlined. The amino acid sequence encoded in the frame in the ﬂanking regions of the ORF is indicated as a three-letter code.
Recognition sequences of BstBI and SnaBI, arising in the vector of Flexi_RBS type are indicated as blue characters. (B) Transfer of the
ORF from the pF1K clone to multiple expression vectors. The ORF sequence in the pF1K clone can be easily transferred to a variety
of other expression vectors with the correct orientation after digestion by SgfI and PmeI. For construction of a C-terminal tag-fusion
clone, SgfI–PmeI ORF sequence must be cloned into SgfI and EcoICRI sites of the expression vector to omit a stop codon arising in
the PmeI site. The appropriate promoter is indicated as an orange arrow in the vectors.
142 ORFeome Cloning of Human Genes Using Flexi System [Vol. 15,and pTD2-Flx vectors. pTD2-Flx is a simple Flexi-type
HaloTag-fusion protein expression vector derived
from the pTD1 vector for the TD system.
19 This
vector has 8-bp restriction enzyme recognition sites
(SgfI and PmeI sites) ﬂanked by the baculovirus poly-
hedrin 50- and 30-UTRs, respectively. pTD2-Gw is a
hybrid expression vector derived from pTD2-Flx,
which has 25-bp Gateway recombination sites, attB1
or attB2, between polyhedrin 50-UTR and SgfI, or
between PmeI and 30-UTR, respectively (Fig. 2A). In
both systems, protein production was directed by in-
vitro-synthesized RNAs. Many ﬂuorescent bands,
probably resulting from proteolytic degradation,
were observed in most samples. The ﬂuorescence
signal intensities of the largest bands were the
expected size for the respective protein products,
Figure 2. Effects of appended sequences surrounding the ORF on translational activity in cell-free protein synthesis systems. (A) Schematic
representation of HaloTag-fusion protein expression vectors, pTD2-Flx (Flexi-type), and pTD2-Gw (Gateway-type). Functional elements
are indicated in the open boxes. attB1 and attB2 represent the Gateway sequences, where speciﬁc recombination reactions occur. (B)
Two types of in vitro protein synthesis experiments were carried out using Flexi-type and Gateway-type clones. ORFs from the 13
different genes listed below were cloned into the two different vectors shown in A and used for in vitro RNA synthesis, followed by
in vitro protein synthesis. Products labeled with HaloTag-TMR ligand and their ﬂuorescence intensities were detected on SDS–PAGE
using FluoroImager FLA3000 (indicated by arrows). Upper panel shows the results of the TransDirect insect cell (TD) and lower
panel shows those of the WGEP. In each panel, protein products from the Flexi-type (F) and Gateway-type vectors (G) are alternately
shown. Ratios of the ﬂuorescence intensities of Gateway products to Flexi products, expressed as percentages, are shown beneath
each panel. An asterisk indicates that protein products were under detection limits. The 13 genes examined here and the numbers
of amino acid residues without HaloTag are as follows: KIAA0409 (lane 1, 457 a.a.); KIAA1248 (lane 2, 358 a.a.); KIAA0491 (lane
3, 366 a.a.); KIAA1238 (lane 4, 387 a.a.); KIAA1788 (lane 5, 412 a.a.); KIAA1604 (lane 6, 909 a.a.); KIAA1649 (lane 7, 422 a.a.);
KIAA1390 (lane 8, 470 a.a.); KIAA2021 (lane 9, 637 a.a.); KIAA0018 (lane 10, 517 a.a.); KIAA1346 (lane 11, 968 a.a.); KIAA1584
(lane 12, 967 a.a.); and KIAA2015 (lane 13, 992 a.a.). (C) Schematic representation of luc2, HaloTag, and Venus expression clones.
Functional elements are indicated in the open boxes. Additional sequences inserted after/before polyhedrin enhancers are shown.
Km1 and Km2 were derived from a kanamycin-resistant gene. RBS represents a ribosome-binding sequence. N–N is equivalent to
pTDFlexi. (D) Results of in vitro protein products assay using luc2, HaloTag, and Venus expression clones. Their activities were
measured as described in Section 2. In the expression clone D5, the polyhedrin 50-UTR 46-bp sequence was replaced with a 10-bp
sequence (AATCGAATTC). Each set of signal intensities was normalized by dividing by that of the N–N, and the averages of three
(Venus and HaloTag), six (TD of luc2), and seven (WGEP of luc2) independent experiments were calculated. Filled bars represent luc2
activity, gray bars represent the HaloTag-TMR ligand signal, and open bars indicate Venus ﬂuorescence intensity.
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comparing the protein productivities of pTD2-Flx
and pTD2-Gw (Fig. 2B, indicated by an arrow). In
the TD system, the ﬂuorescence intensities of 8 out
of 13 HaloTag-fusion proteins in the pTD2-Gw
format were less than 60% as intense as those
derived from pTD2-Flx clones (Fig. 2B, upper lanes:
2, 3, 5, 8–11, and 13). On the other hand, in the
WGEP expression system, the ﬂuorescence intensities
of HaloTag-fusion proteins from ﬁve fusion constructs
in the pTD2-Gw vector were slightly reduced com-
pared with those from pTD2-Flx fusion constructs
(Fig. 2B, lower lanes: 3, 4, 8–10). Interestingly
enough, the ﬂuorescent band patterns of HaloTag-
fusions produced in the TD and WGEP systems were
considerably different from each other, although the
same in-vitro-synthesized RNAs were subjected to
both in vitro protein production systems. These
results indicated that (1) the protein productivity of
both the TD and WGEP systems varied widely from
gene to gene, (2) TD and WGEP had different prefer-
ences for genes in terms of protein production, and
(3) the Gateway recombination site(s) apparently
had an inhibitory effect on translational activity,
which was more prominent in the TD systems.
3.3. Effects of ORF-ﬂanking sequences on translational
activity in cell-free protein synthesis systems
While the different performances of the TD and
WGEP systems were anticipated to some extent, it was
not anticipated that the Gateway recombination sites
would have an inhibitory effect on in vitro protein pro-
duction. Thus, we further pursued the cause of this
apparent inhibitory effect of the Gateway recombina-
tion sites on in vitro protein production. To systemati-
cally examine the effects of the appended sequences
ﬂanking the ORFs on in vitro protein production, we
constructed systematically modiﬁed versions of
expression clones for luc2, HaloTag, and Venus auto-
ﬂuorescent proteins, with different ﬂanking sequences
foreachORF(Fig.2C).ProteinproductionintheTDand
WGEP systems was monitored by measuring luciferase
activity, HaloTag-TMR ligand-binding activity, or the
ﬂuorescence intensity of Venus protein (Fig. 2D). As
shown in Fig. 2C, these clones included ﬂanking
sequences derived from the Gateway attB sites (B1
and/or B2), or parts of the kanamycin-resistant gene
(K1: ACTGGGCACAACAGACAATCGGCTG, or K2:
CCTGTCATCTCACCTTGCTCCTGCC, as examples of
non-speciﬁc sequences) between the translational
enhancer (polyhedrin 50-UTR) and the initiation ATG
codon, and/or between the stop codon and the poly-
hedrin 30-UTR. N–N, an expression clone without any
additional sequences, was the control clone. N–B2
and N–K2 carry additional sequences (B2 and K2,
respectively) only at the 30-ﬂanking site, whereas B1–
N and K1–N have additional sequences (B1 and K1,
respectively) only at the 50-ﬂanking site. K1 and K2
were spacer sequences with equal sizes as B1 and B2
and were not expected to be involved with the
Gateway recombination. We also compared protein
production from the Gateway-type expression vector
(B1–B2) and the modiﬁed vector (B1–K2) in parallel.
Intotal,weexaminedsevendifferentexpressionvectors
in these experiments. Figure 2D shows the relative
activities of luc2, HaloTag, and Venus proteins pro-
duced in the TD and WGEP systems compared with
the N–N type of pTDFlexi vector. Under these exper-
imental conditions, the luciferase expression clones
with attB1 sequence upstream of the ORFs (Fig. 2,
B1–N, B1–B2, and B1–K2) appeared to exhibit only
a slight inhibitory effect in the TD and WGEP systems
in comparison with the pTDFlexi-luc2 construct (N–
N in Fig. 2C). This reduction in protein productivity
seemed to depend on the distance (39 nucleotides)
between the 50 translational enhancer and the
initiationATGbutnotthespeciﬁcnucleotidesequence,
at least in insect TD systems. Expression clones with
short nucleotide sequences of the same length
derived from the kanamycin-resistant gene also
reduced the production of luciferase (Fig. 2D, upper,
K1–N). Such an inhibitory effect was more evident
for HaloTag and Venus protein production in the TD
system. In fact, in the TD system, both HaloTag-TMR-
ligand-binding activity and the ﬂuorescence intensity
of Venus decreased to less than 50% when the
additional sequences were located upstream of the
ORF (Fig. 2D, upper, B1–N, K1–N, B1–B2, and B1–
K2). These results indicated that protein productivity
in the TD system was affected by the increase in dis-
tance between the polyhedrin 50-UTR and the start
ATG, rather than by the ﬂanking nucleotide sequence
of the spacer.
It was reported that the polyhedrin 50-UTR in pTD1
displayed a strong translational enhancing activity,
even in the wheat germ extract and rabbit reticulo-
cyte lysate systems.
19 The inhibitory effect of
sequences upstream of the ORF was prominent in
the TD system but only minor in the WGEP system
(Fig. 2D, lower). Our results also showed that the
expression clone lacking 50-UTR considerably
reduced the productivity of luciferase in both the TD
and WGEP systems, indicating that the translational
enhancer of 50-UTR in pTD1 was functional in each
system (Fig. 2D, D5). On the other hand, translational
activity was largely unaffected by the spacing between
the 30-translational enhancer and the translational
stop codon in all experiments using luc2, HaloTag,
and Venus proteins (Fig. 2D, N–B2, N–K2). Taking
all these results together, we concluded that the
spacing between the 50-translational enhancer and
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productivity, at least in vitro. Although the mechanism
of the inhibitory effect on translational activity by
spacing remains to be elucidated, it appears that
nucleotide spacing between the enhancer and the
initiation codon can sometimes affect translational
activity. Because the distance between the 50-transla-
tional enhancer and the initiation codon is shorter in
the Flexi ORF clone than in the Gateway ORF clone,
these results suggest that the Flexi ORF clone could
be the clone of choice to consistently obtain high
protein productivity in both the TD and WGEP
systems. We consider this as another beneﬁt of using
the Flexi ORF clones, since production level is a
serious concern, particularly when a recombinant
protein is synthesized in vitro.
3.4. Quality check of ORF clones from the viewpoint of
in vitro protein production
Based on the results described above, we conﬁrmed
the functionality of a number of Flexi ORF clones pro-
duced as HaloTag-fusions in in vitro protein pro-
duction systems. For this purpose, we used a
transcription/translation coupled wheat-germ-cell-
free protein synthesis system [TNT SP6 High Yield
Protein Expression System, hereafter abbreviated as
(TNT SP6 HYPES)] because the coupled system is
easier and faster to operate and gives a higher yield
of recombinant protein production than other
uncoupled cell-free protein synthesis systems. Eight
hundred and fourteen ORF sequences in pF1K
clones were transferred to pF3AHT, C-terminal
HaloTag-fusion protein expression vectors, by Flexi
w
cloning methods. One practical problem we encoun-
tered was that the coupled system required a large
amount of expression plasmids to obtain the best
results. Since we planned to use a small volume of
E. coli culture (about 1 mL) to produce the plasmids,
we were concerned that we would not be able to
produce enough DNA to obtain good results in the
TNT system. To solve this problem, we took advantage
of in vitro ampliﬁcation of expression plasmids. We
found that DNA ampliﬁed with a TempliPhi rolling
circle ampliﬁcation kit could be used as template
DNA in the TNT SP6 HYPES without any puriﬁcation.
20
This enabled us to examine the production of a
number of HaloTag-fusions in a high-throughput
manner. As a result, medium-sized and even relatively
large proteins, composed of more than 1000 amino
acid residues, were effectively produced and detected
by Western blot analysis using anti-HaloTag IgG, with
only small amounts of degraded or inappropriately
initiated proteins (Fig. 3A). Moreover, most of the
HaloTag-fusion proteins retained HaloTag ligand-
binding activities (Fig. 3B). Of the 814 pF3AHT
clones tested in the TNT system, 97% produced
recombinant proteins that could be detected by
TMR HaloTag ligand labeling and Western blot analy-
sis using anti-HaloTag antibody. The apparent mol-
ecular masses of the recombinant proteins were
estimated by SDS–PAGE followed by Western blot
analysis using anti-HaloTag antibodies. Most of the
proteins had apparent molecular masses that were
consistent with the numbers of amino acid residues
of the fused proteins (data not shown). Although
the ﬂuorescence intensity of TMR varied widely from
protein to protein in a range of arbitrary ﬂuorescence
units from 10 to 10 000, HaloTag-fusions that
retained the functional characteristics of TMR
ligand-binding were efﬁciently produced. However,
we did observe a tendency of HaloTag-TMR ligand
binding to display decreases in ﬂuorescence intensity
with increases in protein size (Fig. 3C). These results
are most likely explained by decreases in the pro-
duction levels of larger HaloTag-fusions. However, it
could also be explained on the assumption that the
partner proteins may affect HaloTag-TMR ligand-
binding activities. To address this, we examined the
relationship between protein yields and their
HaloTag ligand-binding activities for 53 HaloTag-
fusions. In this experiment, the HaloTag-fusion
protein yields were expressed by the radioactivity of
[
35S]methionine and [
35S]cysteine incorporated into
the proteins and divided by the number that con-
tained methionine and cysteine, while the HaloTag
ligand-binding activities were estimated from the ﬂu-
orescence intensity of Cy5-labeled HaloTag ligand-
bound HaloTag-fusion proteins on SDS–PAGE. The
HaloTag-fusion protein yields and the HaloTag
ligand-binding activities are plotted against the
number of their amino acid residues in Fig. 3D and
E, respectively. In Fig. 3F, the ratios of the HaloTag
ligand-binding activities to the yields of the HaloTag-
fusion proteins are plotted against the number of
amino acid residues. The results indicated that the
molecular HaloTag ligand-binding activities did not
vary widely from fusion to fusion. Based on this
result, we consider that the low ligand-binding activi-
ties observed resulted from low production levels of
HaloTag-fusion proteins, although there may have
been some exceptions.
3.5. Subcellular localization of HaloTag-fusion proteins
and MGFP-fusion proteins
In general, information on the subcellular localiz-
ation of proteins provides us with an important clue
on potential protein function. Thus, we accumulated
data of the subcellular localizations using green ﬂuor-
escent protein (GFP)–ORF fusions constructed using
the Gateway system. It was important for us to
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HaloTag-fusions was consistent with the subcellular
localization observed for GFP-fusions. First, we
examined whether or not the HaloTag protein could
be located in an expected subcellular compartment
upon fusion of localization signals in COS-7 cells. To
Figure 3. Expression of recombinant HaloTag-fusion proteins in an in vitro transcription/translation coupled protein synthesis system.
Example of HaloTag-fusion proteins expressed in vitro. TempliPhi-ampliﬁed 48 pF3AHT DNA clones were used for an in vitro
transcription/translation system using wheat germ extract (TNT SP6 HYPE System). The recombinant HaloTag-fusion proteins were
separated by SDS–PAGE. (A) The recombinant proteins were detected by Western blot analysis using anti-HaloTag antibody. Three
bands indicated by asterisks are the signals derived from wheat germ endogenous proteins. (B) The recombinant proteins were
labeled by the HaloTag-TMR ligand after the reaction and detected with FLA3000. The corresponding gene numbers for the
HaloTag-fusion recombinant proteins in each lane of (A) and (B) are indicated as follows: 1, KIAA1231; 2, KIAA0720; 3, KIAA1426;
4, KIAA0386; 5, KIAA0651; 6, KIAA0010; 7, KIAA0543; 8, KIAA0987; 9, KIAA1386; 10, KIAA1902; 11, KIAA0594; 12, KIAA1450;
13, KIAA1973; 14, KIAA0055; 15, KIAA0835; 16, KIAA1531; 17, KIAA0750; 18, KIAA1714; 19, KIAA1738; 20, KIAA1106; 21,
KIAA1525; 22, KIAA0229; 23, KIAA0182; 24, KIAA0954; 25, KIAA1904; 26, KIAA0020; 27, KIAA0028; 28, KIAA0076; 29,
KIAA0150; 30, KIAA0152; 31, KIAA0153; 32, KIAA0168; 33, KIAA0186; 34, KIAA0205; 35, KIAA0223; 36, KIAA0278; 37,
KIAA0680; 38, KIAA1184; 39, KIAA1245; 40, KIAA1399; 41, KIAA1871; 42, KIAA1857; 43, KIAA1912; 44, KIAA1916; 45,
KIAA1917; 46, KIAA1942; 47, KIAA1949; and 48, KIAA1957. The positions of MagicMark XP Western Protein Standard (M) are
indicated in kDa on the left. Relationship between TMR-ligand-binding activities and sizes of HaloTag-fusion proteins synthesized in
the TNT SP6 HYPE system. (C) Fluorescence intensities of the HaloTag-TMR ligand covalently bound to the recombinant proteins
(vertical axis) are plotted against the number of amino acid residues without HaloTag (horizontal axis). (D) Yields of the HaloTag-
fusion proteins were estimated as the radioactivity of [
35S]methionine and [
35S]cysteine-labeled proteins calculated by BAS2000
imaging analyzer after SDS–PAGE and the value was divided by the number that contained methionine and cysteine. Yields (vertical
axis) are plotted against the number of amino acid residues (horizontal axis) (closed circles). (E) HaloTag ligand-binding activity was
estimated by measuring the ﬂuorescence intensities of the HaloTag Cy5 ligand covalently bound to the HaloTag-fusion proteins after
SDS–PAGE by FluoroImager FLA3000. The activities (vertical axis) are plotted against the number of amino acid residues (horizontal
axis) (gray circles). (F) Ratios of HaloTag ligand-binding activities to HaloTag-fusion protein yields (vertical axis) are plotted against
the number of amino acid residues (horizontal axis) (open circles). The 53 human genes used for protein production in (D), (E), and
(F) are as follows: KIAA0024, KIAA0027, KIAA0057, KIAA0137, KIAA0151, KIAA0199, KIAA0230, KIAA0238, KIAA0352, KIAA0412,
KIAA0416, KIAA0422, KIAA0441, KIAA0550, KIAA0557, KIAA0606, KIAA0623, KIAA0644, KIAA0722, KIAA0798, KIAA0813,
KIAA0848, KIAA0936, KIAA0939, KIAA0968, KIAA1020, KIAA1048, KIAA1142, KIAA1198, KIAA1225, KIAA1227, KIAA1246,
KIAA1253, KIAA1264, KIAA1337, KIAA1369, KIAA1382, KIAA1431, KIAA1469, KIAA1477, KIAA1559, KIAA1572, KIAA1580,
KIAA1851, KIAA1852, KIAA1874, KIAA1910, KIAA2003, ABCA3, PAK6, STK38, PINK1, and GPRC5.
146 ORFeome Cloning of Human Genes Using Flexi System [Vol. 15,Figure 4. Subcellular localization of HaloTag-fusion proteins in cultured cells. (A) Subcellular localization of transiently expressed HaloTag
proteins with various signal sequences. COS-7 cells were transfected with pFC8A expression clones for HaloTag proteins containing
signal sequences, such as plasma-membrane-localized signal (Memb), nuclear localization signal (NLS), ER targeting sequence (ER),
Golgi-localized signal (Golgi), and mitochondria-localized signal (Mito) and HaloTag pHT2 vector which expresses HaloTag ORF
(HaloTag). HaloTag-fusion proteins were labeled with medium containing 1-mM HaloTag-TMR ligand (red) for 15 min, washed and
incubated for 30 min. Nuclei were stained with Hoechst33342 (blue). Cells were observed by BioZERO ﬂuorescence microscope
(TMR). Photos labeled with Hoechst33342 and TMR ligand are merged (TMR þ Hoechst). (B) Comparison of subcellular
localizations between HaloTag- and MGFP-fusion proteins. HEK293 cells were simultaneously transfected with HaloTag-fusion (red)
and MGFP-fusion protein (green) expression clones. The HaloTag-fusion proteins (red) and nuclei (blue) were observed as described
above, except that the ﬁnal incubation before observation was 24 h. Photos labeled with Hoechst33342 are merged with those of
MGFP- or HaloTag-fusion proteins (MGFP or HaloTag). Gene symbols and alias names are indicated beneath the photos.
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HaloTag protein containing signal sequences, such as
membane-localized signal (Memb),
21 nuclear localiz-
ation signal (NLS),
22 endoplasmic reticulum targeting
sequence (ER),
23 Golgi-localized signal (Golgi),
24 and
mitochondrial targeting sequence (Mito).
25 These
sequences were all placed at the N-terminal region
of the HaloTag proteins. Eighteen hours after transfec-
tion of these constructs into COS-7 cells, the HaloTag-
fusion proteins were labeled with the TMR ligand and
observed with a ﬂuorescence microscopy system.
Figure 4A shows that all fused proteins were detected
in an expected subcellular compartment, indicating
that HaloTag proteins do not inhibit the function of
these subcellular localization signals. Next, we directly
evaluated whether HaloTag-fusion proteins were co-
localized with the same GFP-fusion proteins when
both fusions were expressed in the same cells. C-term-
inal HaloTag- and MGFP-fusion protein expression
clones were prepared by the Flexi
w cloning system
using the Flexi ORF clones we prepared and pFC8A
(HaloTag) and pFC8A (MGFP) vectors. After co-trans-
fection of HEK293 cells with the same ORF clone
fused to the two different fusion tags, HaloTag-
fusion proteins were labeled with the TMR ligand
and then the ﬂuorescence images were obtained for
TMR- (red) and MGFP-labeled (green) proteins for
40 ORFs. Examples of the cellular localization of the
fusion proteins are shown in Fig. 4B. Among them,
subcellular locations of glucocorticoid modulatory
element-binding protein 2 (GMEB-2/KIAA1269),
phosphatidylserine synthase 1 (PTDSS1/KIAA0024),
membrane-bound transcription factor site-1 protease
(MBTPS1/KIAA0091), and transmembrane protein
127 (TMEM127/KIBB2508) are reported in the
UniProt Knowledgebase as nucleus/cytoplasm,
membrane, endoplasmic reticulum/Golgi apparatus,
and membrane, respectively (http://ca.expasy.org/
sprot/).
26 In contrast, the subcellular location of
Mesoderm development candidate 2 (MESDC2/
KIAA0081) is not mentioned and Secernin-1
(SCRN1/KIAA0193) is predicted to exist in the cyto-
plasm from similarities found in the database. The
subcellular localizations of the 40 HaloTag-fusion
proteins analyzed here were the same as those for
MGFP-fusion proteins. These results indicate that
HaloTag-fusion proteins can be used as an alternative
for subcellular localization analysis in place of conven-
tional autoﬂuorescent proteins.
In conclusion, a complete set of ORF resources in
various expression-ready clone formats clearly can
serve as versatile sets of reagents for functional geno-
mics research. The rapid, easy, and assured transfer of
ORF sequences into different expression vectors is
highly critical for this purpose, since many ORF
clones are used in combination with protein fusion
tags that allow functional analysis. Within this
context, we selected a HaloTag protein as a fusion
partner because we considered that HaloTag
w tech-
nology would provide a wide range of utilities that
include detection and puriﬁcation as well as adapta-
bility in functional studies. In fact, we have successfully
used HaloTag-fusion proteins in other studies for
pulse-chase labeling, protein–protein interaction,
and chromosomal immunoprecipitation-like analyses
along with bioimaging (unpublished data). In this
report, we have shown that the Flexi
w cloning
method is suitable for the preparation of a large
number of ORF clones into the pF1K vector and
allows seamless implementation of HaloTag
w
interchangeable technology. Moreover, we have
demonstrated that most human proteins were efﬁ-
ciently expressed as HaloTag-fusions in an in vitro
coupled protein expression system, as well as in cul-
tured mammalian cells. The resultant HaloTag-
fusion proteins were biochemically active and success-
fully used for analyses of subcellular localization as an
alternative to conventional autoﬂuorescent proteins.
Based on these results, we will accumulate a
number of human ORF clones in the form of
expression plasmids for HaloTag-fusion proteins,
either C- or N-terminal fusions, in our ORFeome
project since they will be directly used for functional
studies, as well as for further transfer to another
vector. HaloTag
w technology provides a single fusion
tag that can be utilized for a variety of structural
and functional proteomic studies. Although there
are a number of ORFeome resources for human
genes that have been generated by Gateway recombi-
national cloning,
27 a set of human Flexi ORF clones
prepared as described would provide the research
community with an important alternative for large-
scale proteomic studies and a tool for individual
research laboratories.
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